GlobeNewswire: Agios Pharmaceuticals, Inc. Contains the last 10 of 318 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:35:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/05/2840286/0/en/Agios-to-Present-at-the-Leerink-Partners-Global-Biopharma-Conference-on-March-12-2024.html?f=22&fvtc=4&fvtv=22798Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 20242024-03-05T12:00:00Z<![CDATA[CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024, at 10:00 a.m. ET.]]>https://www.globenewswire.com/news-release/2024/02/22/2833514/0/en/Agios-to-Present-at-the-TD-Cowen-44th-Annual-Health-Care-Conference-on-March-4-2024.html?f=22&fvtc=4&fvtv=22798Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 20242024-02-22T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, at 2:10 p.m. ET.]]>https://www.globenewswire.com/news-release/2024/02/15/2829806/0/en/Agios-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html?f=22&fvtc=4&fvtv=22798Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights2024-02-15T12:00:00Z<![CDATA[– Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia –]]>https://www.globenewswire.com/news-release/2024/02/02/2822756/0/en/Agios-to-Webcast-Conference-Call-of-Fourth-Quarter-and-Year-End-2023-Financial-Results-on-February-15-2024.html?f=22&fvtc=4&fvtv=22798Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 20242024-02-02T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 15, 2024, at 8:00 a.m. ET to report its fourth quarter and year end 2023 financial results and other business highlights.]]>https://www.globenewswire.com/news-release/2024/01/08/2805239/0/en/Agios-Announces-Key-Anticipated-2024-Milestones-Across-Rare-Disease-Portfolio.html?f=22&fvtc=4&fvtv=22798Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio2024-01-08T12:00:00Z<![CDATA[– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia –]]>https://www.globenewswire.com/news-release/2024/01/03/2803114/0/en/Agios-Announces-Phase-3-ENERGIZE-Study-of-Mitapivat-Met-Primary-Endpoint-and-Both-Key-Secondary-Endpoints-in-Adults-with-Non-Transfusion-Dependent-Alpha-or-Beta-Thalassemia.html?f=22&fvtc=4&fvtv=22798Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia2024-01-03T11:30:00Z<![CDATA[–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo –]]>https://www.globenewswire.com/news-release/2024/01/02/2802565/0/en/Agios-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference-on-January-10-2024.html?f=22&fvtc=4&fvtv=22798Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 20242024-01-02T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 7:30 a.m. PT.]]>https://www.globenewswire.com/news-release/2023/12/10/2793450/0/en/Agios-Presents-Positive-Results-from-Phase-2-Portion-of-the-RISE-UP-Pivotal-Study-in-Sickle-Cell-Disease-at-65th-ASH-Annual-Meeting-and-Exposition.html?f=22&fvtc=4&fvtv=22798Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition2023-12-10T00:00:00Z<![CDATA[– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo –]]>https://www.globenewswire.com/news-release/2023/11/20/2783104/0/en/Agios-Announces-Clinical-Proof-of-Concept-in-Phase-2a-Trial-of-AG-946-for-the-Treatment-of-Anemia-in-Lower-Risk-Myelodysplastic-Syndromes.html?f=22&fvtc=4&fvtv=22798Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes2023-11-20T12:00:00Z<![CDATA[– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint –]]>https://www.globenewswire.com/news-release/2023/11/02/2772433/0/en/Agios-Pharmaceuticals-to-Present-Broad-Set-of-Clinical-and-Translational-Data-in-Rare-Blood-Disorders-at-65th-ASH-Annual-Meeting-and-Exposition.html?f=22&fvtc=4&fvtv=22798Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition2023-11-02T13:05:00Z<![CDATA[– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support Advancement to Phase 3 Portion of RISE UP –]]>